We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Personalis (PSNL) Moves 20.5% Higher: Will This Strength Last?
Read MoreHide Full Article
Personalis (PSNL - Free Report) shares ended the last trading session 20.5% higher at $10.28. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 48.9% gain over the past four weeks.
The surge in share price follows Personalis' announcement of new data from AstraZeneca’s late-stage lung cancer study (LAURA), which utilized its highly sensitive molecular residual disease (MRD) test, NeXT Personal. The analysis showed that the company’s test detected MRD progression with a median lead time of five months ahead of disease progression as assessed by a panel of independent experts.
This provider of contract research and genomic information is expected to post quarterly loss of $0.28 per share in its upcoming report, which represents a year-over-year change of +56.3%. Revenues are expected to be $13.7 million, down 46.7% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Personalis, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on PSNL going forward to see if this recent jump can turn into more strength down the road.
Personalis is part of the Zacks Medical - Generic Drugs industry. Taysha Gene Therapies, Inc. (TSHA - Free Report) , another stock in the same industry, closed the last trading session 4.9% lower at $5.08. TSHA has returned 84.1% in the past month.
For Taysha Gene Therapies, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.09. This represents no change from what the company reported a year ago. Taysha Gene Therapies currently has a Zacks Rank of #3 (Hold).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Personalis (PSNL) Moves 20.5% Higher: Will This Strength Last?
Personalis (PSNL - Free Report) shares ended the last trading session 20.5% higher at $10.28. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 48.9% gain over the past four weeks.
The surge in share price follows Personalis' announcement of new data from AstraZeneca’s late-stage lung cancer study (LAURA), which utilized its highly sensitive molecular residual disease (MRD) test, NeXT Personal. The analysis showed that the company’s test detected MRD progression with a median lead time of five months ahead of disease progression as assessed by a panel of independent experts.
This provider of contract research and genomic information is expected to post quarterly loss of $0.28 per share in its upcoming report, which represents a year-over-year change of +56.3%. Revenues are expected to be $13.7 million, down 46.7% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Personalis, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on PSNL going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Personalis is part of the Zacks Medical - Generic Drugs industry. Taysha Gene Therapies, Inc. (TSHA - Free Report) , another stock in the same industry, closed the last trading session 4.9% lower at $5.08. TSHA has returned 84.1% in the past month.
For Taysha Gene Therapies, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.09. This represents no change from what the company reported a year ago. Taysha Gene Therapies currently has a Zacks Rank of #3 (Hold).